Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC and Toripalimab in HER2+ Muscle-Invasive Bladder Cancer
NCT05356351Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2022
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin, toripalimab in Muscle Invasive Bladder Cancer (MIBC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start May 2022; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT05356351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05356351.